Vericel Corporation (VCEL)
| Bid | 45 |
| Market Cap | 2.3B |
| Revenue (ttm) | 240.42M |
| Net Income (ttm) | 10.5M |
| EPS (ttm) | 0.19 |
| PE Ratio (ttm) | 242.21 |
| Forward PE | 127.47 |
| Analyst | Strong Buy |
| Ask | 50.51 |
| Volume | 367,735 |
| Avg. Volume (20D) | 414,303 |
| Open | 46.47 |
| Previous Close | 46.42 |
| Day's Range | 45.41 - 46.72 |
| 52-Week Range | 39.12 - 63.00 |
| Beta | 1.79 |
About VCEL
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epic...
Analyst Forecast
According to 6 analyst ratings, the average rating for VCEL stock is "Strong Buy." The 12-month stock price forecast is $63, which is an increase of 36.90% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
4 weeks ago · seekingalpha.com
Vericel Corporation (VCEL) Q4 2024 Earnings Conference Call TranscriptVericel Corporation (NASDAQ:VCEL ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Nick Colangelo - CEO Joe Mara - CFO Eric Burns - VP, Finance and IR Conference Cal...
